In this study, we demonstrated that systemic BBR treatment effectively inhibited inducible DUX4 expression at both the mRNA and protein levels in one of the most utilized FSHD mouse models, ACTA1-MCM/FLExDUX4. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.